-
Why did NICE reject the funding for donanemab?
NICE rejected donanemab due to its insufficient benefits compared to its high cost. According to Helen Knight from NICE, while the drug may slow cognitive decline by four to seven months, this benefit does not justify the financial burden on the NHS.
-
What are the alternatives being explored for Alzheimer's treatment?
In light of the rejection of donanemab and lecanemab, researchers are exploring the repurposing of existing medications as potential alternatives. This shift aims to find more cost-effective solutions that can provide meaningful benefits to patients without the high costs associated with new drugs.
-
How does this decision impact patients and families?
The rejection of donanemab may leave patients and families feeling frustrated and concerned about the future of Alzheimer's treatment. It raises questions about access to effective therapies and the potential for a two-tier healthcare system, where only those who can afford private treatment may benefit from new drugs.
-
What are the side effects of donanemab?
While donanemab is not a cure for Alzheimer's, it has raised concerns regarding potential side effects. These can include brain swelling and bleeding, which have been reported in some patients. The risk of these side effects contributes to the overall hesitance in approving the drug for widespread use.
-
What does the future hold for Alzheimer's drug development?
The future of Alzheimer's drug development may focus on more cost-effective treatments and repurposing existing medications. Ongoing research aims to find therapies that can effectively modify the disease while being financially viable for healthcare systems like the NHS.